.jpg?format=webp&width=780)
This study investigates the combination of two drugs, TAK981 and 5-Aza-2’-deoxycytidine, for the treatment of MYC-driven hematopoietic malignancies, including Burkitt lymphoma and diffuse large B-cell lymphoma. The study found that the combination of the two drugs led to increased DNA damage and reduced cell proliferation in vitro. In vivo experiments showed a significant reduction in the outgrowth of Burkitt lymphoma in an orthotopic xenograft model. The study highlights the potential of combining drugs with complementary mechanisms to improve cancer treatment efficacy.
Like
Save
Share